322 related articles for article (PubMed ID: 26068539)
81. Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism.
Devabhakthuni S; Yoon CH; Pincus KJ
J Pharm Pract; 2016 Aug; 29(4):392-405. PubMed ID: 25634013
[TBL] [Abstract][Full Text] [Related]
82. New oral anticoagulants.
Galanis T; Thomson L; Palladino M; Merli GJ
J Thromb Thrombolysis; 2011 Apr; 31(3):310-20. PubMed ID: 21327511
[TBL] [Abstract][Full Text] [Related]
83. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
Mendell J; Noveck RJ; Shi M
Br J Clin Pharmacol; 2013 Apr; 75(4):966-78. PubMed ID: 22924409
[TBL] [Abstract][Full Text] [Related]
84. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Yin OQ; Tetsuya K; Miller R
Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
[TBL] [Abstract][Full Text] [Related]
85. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment.
Koretsune Y; Yamashita T; Kimura T; Fukuzawa M; Abe K; Yasaka M
Circ J; 2015; 79(7):1486-95. PubMed ID: 25925842
[TBL] [Abstract][Full Text] [Related]
86. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Mendell J; Johnson L; Chen S
J Clin Pharmacol; 2015 Dec; 55(12):1395-405. PubMed ID: 26011596
[TBL] [Abstract][Full Text] [Related]
87. [Research and development strategy of antithrombotic agents: pharmacology of the oral factor Xa-inhibitor edoxaban].
Morishima Y; Shibano T
Nihon Yakurigaku Zasshi; 2010 Aug; 136(2):83-7. PubMed ID: 20702966
[No Abstract] [Full Text] [Related]
88. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V.
Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Fukuzawa M; Abe K; Tachibana S
Thromb J; 2015; 13():27. PubMed ID: 26269694
[TBL] [Abstract][Full Text] [Related]
89. Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program.
Unverdorben M; Colonna P; Jin J; Köhler S; Santamaria A; Saxena M; Borrow A; Chen C; von Heymann C; Vanassche T
Clin Appl Thromb Hemost; 2024; 30():10760296241260728. PubMed ID: 38881370
[No Abstract] [Full Text] [Related]
90. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule.
Parasrampuria DA; Kanamaru T; Connor A; Wilding I; Ogata K; Shimoto Y; Kunitada S
J Clin Pharmacol; 2015 Nov; 55(11):1286-92. PubMed ID: 25969414
[TBL] [Abstract][Full Text] [Related]
91. Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers.
Yin OQ; Miller R
Clin Drug Investig; 2014 Oct; 34(10):743-52. PubMed ID: 25186833
[TBL] [Abstract][Full Text] [Related]
92. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.
Kuroda Y; Hirayama C; Hotoda H; Nishikawa Y; Nishiwaki A
Vasc Health Risk Manag; 2013; 9():593-8. PubMed ID: 24124376
[TBL] [Abstract][Full Text] [Related]
93. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Mendell J; Zahir H; Matsushima N; Noveck R; Lee F; Chen S; Zhang G; Shi M
Am J Cardiovasc Drugs; 2013 Oct; 13(5):331-42. PubMed ID: 23784266
[TBL] [Abstract][Full Text] [Related]
94. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Mendell J; Chen S; He L; Desai M; Parasramupria DA
Clin Drug Investig; 2015 Jul; 35(7):447-53. PubMed ID: 26068927
[TBL] [Abstract][Full Text] [Related]
95. Edoxaban and the need for outcomes-based NOAC dosing.
Patel MR; Washam JB
Lancet; 2015 Jun; 385(9984):2232-3. PubMed ID: 25769359
[No Abstract] [Full Text] [Related]
96. Clinical Assessment of Postoperative Anemia Associated with Edoxaban in Patients Undergoing Total Knee Arthroplasty Compared to Fondaparinux.
Izushi Y; Takami Y; Shiota N; Tetsunaga T; Ookura Y; Shimada K; Egawa T; Kiuchi T; Sato T; Takuma R
Biol Pharm Bull; 2016; 39(4):516-23. PubMed ID: 27040624
[TBL] [Abstract][Full Text] [Related]
97. Use of Oral Anticoagulants According to the Degree of Renal Impairment in Japanese Patients With Atrial Fibrillation--Which Non-Vitamin K Antagonist Oral Anticoagulant to Select?
Ikeda T
Circ J; 2015; 79(7):1441-3. PubMed ID: 26028323
[No Abstract] [Full Text] [Related]
98. Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation.
Eymin G; Jaffer AK
J Thromb Thrombolysis; 2014; 37(2):87-96. PubMed ID: 24022820
[TBL] [Abstract][Full Text] [Related]
99. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.
Jönsson S; Simonsson US; Miller R; Karlsson MO
J Clin Pharmacol; 2015 Nov; 55(11):1268-79. PubMed ID: 25966665
[TBL] [Abstract][Full Text] [Related]
100. The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease.
van Ommen CH; Albisetti M; Chan AK; Estepp J; Jaffray J; Kenet G; Young G; Dave J; Grosso MA; Duggal A
Res Pract Thromb Haemost; 2020 Jul; 4(5):886-892. PubMed ID: 32685899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
